vs
Side-by-side financial comparison of ImmunityBio, Inc. (IBRX) and PLAYSTUDIOS, Inc. (MYPS). Click either name above to swap in a different company.
PLAYSTUDIOS, Inc. is the larger business by last-quarter revenue ($55.4M vs $38.3M, roughly 1.4× ImmunityBio, Inc.). PLAYSTUDIOS, Inc. runs the higher net margin — -24.7% vs -161.8%, a 137.1% gap on every dollar of revenue. On growth, ImmunityBio, Inc. posted the faster year-over-year revenue change (407.0% vs -18.3%). PLAYSTUDIOS, Inc. produced more free cash flow last quarter ($3.6M vs $-71.3M).
ImmunityBio, Inc. is a clinical-stage biotechnology company focused on developing next-generation immunotherapies and vaccine candidates targeting multiple cancer types and infectious diseases. It operates mainly in the U.S. market, with core R&D segments including cell therapy, antibody therapeutics, and targeted vaccine platforms designed to enhance patient treatment outcomes.
PLAYSTUDIOS, Inc. develops and publishes free-to-play social and casual casino games for mobile, desktop and social platforms. It operates a loyalty rewards program that lets players redeem in-game achievements for real-world benefits including travel, dining and event tickets, serving markets across North America, Europe and Asia Pacific.
IBRX vs MYPS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $38.3M | $55.4M |
| Net Profit | $-61.9M | $-13.7M |
| Gross Margin | 99.0% | — |
| Operating Margin | -169.0% | -17.7% |
| Net Margin | -161.8% | -24.7% |
| Revenue YoY | 407.0% | -18.3% |
| Net Profit YoY | -4.7% | 38.9% |
| EPS (diluted) | $-0.06 | $-0.12 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $38.3M | $55.4M | ||
| Q3 25 | $32.1M | $57.6M | ||
| Q2 25 | $26.4M | $59.3M | ||
| Q1 25 | $16.5M | $62.7M | ||
| Q4 24 | $7.6M | $67.8M | ||
| Q3 24 | $6.1M | $71.2M | ||
| Q2 24 | — | $72.6M | ||
| Q1 24 | — | $77.8M |
| Q4 25 | $-61.9M | $-13.7M | ||
| Q3 25 | $-67.3M | $-9.1M | ||
| Q2 25 | $-92.6M | $-2.9M | ||
| Q1 25 | $-129.6M | $-2.9M | ||
| Q4 24 | $-59.2M | $-22.4M | ||
| Q3 24 | $-85.7M | $-3.1M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-567.0K |
| Q4 25 | 99.0% | — | ||
| Q3 25 | 99.4% | — | ||
| Q2 25 | 99.5% | — | ||
| Q1 25 | 99.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | -169.0% | -17.7% | ||
| Q3 25 | -173.5% | -13.6% | ||
| Q2 25 | -269.8% | -5.9% | ||
| Q1 25 | -390.1% | -4.4% | ||
| Q4 24 | -919.0% | -33.1% | ||
| Q3 24 | -1314.3% | -6.7% | ||
| Q2 24 | — | -5.5% | ||
| Q1 24 | — | -2.2% |
| Q4 25 | -161.8% | -24.7% | ||
| Q3 25 | -209.8% | -15.8% | ||
| Q2 25 | -350.3% | -5.0% | ||
| Q1 25 | -784.9% | -4.6% | ||
| Q4 24 | -783.4% | -33.1% | ||
| Q3 24 | -1404.0% | -4.3% | ||
| Q2 24 | — | -3.6% | ||
| Q1 24 | — | -0.7% |
| Q4 25 | $-0.06 | $-0.12 | ||
| Q3 25 | $-0.07 | $-0.07 | ||
| Q2 25 | $-0.10 | $-0.02 | ||
| Q1 25 | $-0.15 | $-0.02 | ||
| Q4 24 | $-0.08 | $-0.18 | ||
| Q3 24 | $-0.14 | $-0.02 | ||
| Q2 24 | — | $-0.02 | ||
| Q1 24 | — | $0.00 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $242.8M | $104.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-500.5M | $227.9M |
| Total Assets | $501.9M | $290.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $242.8M | $104.9M | ||
| Q3 25 | $257.8M | $106.3M | ||
| Q2 25 | $153.7M | $112.9M | ||
| Q1 25 | $61.6M | $107.1M | ||
| Q4 24 | $149.8M | $109.2M | ||
| Q3 24 | $130.4M | $105.2M | ||
| Q2 24 | — | $106.3M | ||
| Q1 24 | — | $127.0M |
| Q4 25 | $-500.5M | $227.9M | ||
| Q3 25 | $-524.3M | $238.9M | ||
| Q2 25 | $-570.7M | $245.3M | ||
| Q1 25 | $-591.4M | $244.1M | ||
| Q4 24 | $-489.1M | $244.7M | ||
| Q3 24 | $-745.1M | $265.2M | ||
| Q2 24 | — | $263.6M | ||
| Q1 24 | — | $288.4M |
| Q4 25 | $501.9M | $290.6M | ||
| Q3 25 | $519.0M | $299.2M | ||
| Q2 25 | $402.1M | $316.2M | ||
| Q1 25 | $303.8M | $313.8M | ||
| Q4 24 | $382.9M | $323.0M | ||
| Q3 24 | $364.6M | $330.6M | ||
| Q2 24 | — | $333.4M | ||
| Q1 24 | — | $357.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-70.4M | $3.7M |
| Free Cash FlowOCF − Capex | $-71.3M | $3.6M |
| FCF MarginFCF / Revenue | -186.2% | 6.5% |
| Capex IntensityCapex / Revenue | 2.4% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-308.8M | $25.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-70.4M | $3.7M | ||
| Q3 25 | $-68.9M | $5.7M | ||
| Q2 25 | $-79.7M | $13.6M | ||
| Q1 25 | $-85.9M | $3.3M | ||
| Q4 24 | $-85.1M | $11.6M | ||
| Q3 24 | $-98.8M | $14.6M | ||
| Q2 24 | — | $14.5M | ||
| Q1 24 | — | $5.0M |
| Q4 25 | $-71.3M | $3.6M | ||
| Q3 25 | $-69.6M | $5.4M | ||
| Q2 25 | $-80.8M | $13.2M | ||
| Q1 25 | $-87.0M | $3.2M | ||
| Q4 24 | $-87.3M | $11.5M | ||
| Q3 24 | $-101.6M | $13.9M | ||
| Q2 24 | — | $12.8M | ||
| Q1 24 | — | $3.6M |
| Q4 25 | -186.2% | 6.5% | ||
| Q3 25 | -217.2% | 9.3% | ||
| Q2 25 | -305.9% | 22.3% | ||
| Q1 25 | -526.9% | 5.1% | ||
| Q4 24 | -1155.4% | 16.9% | ||
| Q3 24 | -1663.2% | 19.6% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 4.6% |
| Q4 25 | 2.4% | 0.2% | ||
| Q3 25 | 2.3% | 0.5% | ||
| Q2 25 | 4.1% | 0.7% | ||
| Q1 25 | 6.8% | 0.2% | ||
| Q4 24 | 28.0% | 0.2% | ||
| Q3 24 | 45.7% | 0.9% | ||
| Q2 24 | — | 2.4% | ||
| Q1 24 | — | 1.9% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
